Project portfolio
NOSO-502 BVL-GSK098 Gepotidacin tissue distribution ERA4TB-01 ERA4TB-02 ERA4TB-03 ERA4TB-04 ERA4TB-06 ERA4TB-09 ERA4TB-10 BC1 back up RespiriTB RespiriNTM

NOSO-502

NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.

BVL-GSK098

Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line TB treatments.

Gepotidacin tissue distribution

Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

ERA4TB-01

Molecule targeting cholesterol catabolism of mycobacteria.

ERA4TB-02

Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.

ERA4TB-03

Compounds targeting energy metabolism (electron chain transport).

ERA4TB-04

Compound targeting lysine transfer RNA synthase (LysS), which is an essential gene as assessed by transposon mutagenesis.

ERA4TB-06

Mycobacterial membrane protein Large 3 compounds with potent in vitro inhibitory and bactericidal activity against M tuberculosis.

ERA4TB-09

Natural product analogs active against Mycobacterium tuberculosis.

ERA4TB-10

Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase.

BC1 back up

Lead optimization program on BC1 inhibitors.

RespiriTB

Mycothione reductase target exploration.

RespiriNTM

Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.